VSV-Pseudovirus_SARS-CoV-2 Beta Luciferase, ReVacc Scientific

Supplier: ReVacc Scientific

G99O57-200UL G99O57-1ML
76515-528EA 643.72 USD
76515-528 76515-530
VSV-Pseudovirus_SARS-CoV-2 Beta Luciferase, ReVacc Scientific
Vectors, Plasmids and Libraries

This pseudotyped virus uses recombinant Vesicular Stomatitis Virus (rVSV) to carry spike protein of SARS-CoV-2 (GenBank: MN908947) with multiple mutations identified in Beta variant: L18F, D80A, D215G, L242-244del, R246I, K417N, E484K, N501Y, D614G, and A701V. The spike protein has a 18-aa cytoplasmic tail truncation for optimal infection.


Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See the titration result showing the undiluted pseudovirus generates signal ~10000-fold higher than uninfected control (cell alone as background). The neutralizing activity of two published control mAbs (Science, 2020: 369, p643) was tested by using this pseudotyped virus.


The pseudotypes should be handled using BSL-2 containment practices. Applications include Anti-SARS-CoV-2 neutralizing antibody screening at high throughput, Anti-SARS-CoV-2 drug screening at high throughput and SARS-CoV-2 pseudovirus transduction of target cells for viral entry and functional studies.


Envase: Shipping with dry ice. Require −80 °C storage. Multiple freeze/Thaw cycles will reduce its sensitivity. Recommend only one cycle. Aliquot after the first thaw.


Precaución: Handle it in biosafety cabinet in BSL-2. Contacted tips and tubes should be decontaminated by 10% disinfecting bleach. For research use only.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR